SCHEMBL15512

SCHEMBL15512

CCOC(=O)/C=C/c1cccc(C(C)C)c1C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
TTR P02766 1/20 0.43
DPP4 P27487 1/20 0.43
CYP3A4 P08684 2/20 0.42
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
NLRP3 Q96P20 3/20 0.42
ESR1 P03372 2/20 0.40
MAOB P27338 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21716655 0.87 CA12 (0.49) KDM4ECA12CA1CA2CA7
SCHEMBL28909604 0.87 CA12 (0.49) KDM4ECA12CA1CA2CA7
SCHEMBL579354 0.84 KDM4E (0.54) KDM4ECA12CA1CA2CA7
SCHEMBL19289773 0.83 CA12 (0.43) CA12CA1CA2CA7CA9
SCHEMBL27448132 0.81 CA12 (0.43) KDM4ECA12CA1CA2CA7
SCHEMBL20358015 0.80 CA12 (0.48) KDM4ECA12CA1CA2CA7
SCHEMBL1173259 0.79 KDM4E (0.66) KDM4ECA1CA2CYP3A4MAPT
SCHEMBL10783189 0.78 CA12 (0.59) KDM4ECA12CA1CA2CA7
SCHEMBL11054639 0.77 CA12 (0.57) KDM4ECA12CA1CA2CA7
SCHEMBL31016123 0.76 CA12 (0.42) KDM4ECA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1715 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130195779-A1 SUBSTANTIVE SUNSCREEN FORMULATION MARY KAY INC. (US) 2013-08-01 US claimed
US-20130164232-A1 SUBSTANTIVE SUNSCREEN FORMULATION MARY KAY INC. (US) 2013-06-27 US claimed
US-20130156711-A1 TOPICAL SKIN CARE FORMULATION MARY KAY INC. (US) 2013-06-20 US claimed
US-20060073106-A1 Novel stabilized cinnamic ester sunscreen compositions DSM IP ASSETS B.V. (NL) 2006-04-06 US claimed
EP-1589940-A1 NOVEL STABILIZED CINNAMIC ESTER SUNSCREEN COMPOSITIONS DSM IP Assets B.V. (NL) 2005-11-02 EP claimed
WO-2004069216-A1 NOVEL STABILIZED CINNAMIC ESTER SUNSCREEN COMPOSITIONS DSM IP ASSETS B.V. (CH) 2004-08-19 WO claimed
US-20020131939-A1 Hair protection compositions ROCHE VITAMINS INC. 2002-09-19 US claimed
CN-122055135-A Cosmetic compositions and methods of use thereof 玫琳凯有限公司 2026-05-15 CN disclosed
EP-4739399-A2 METHODS AND COMPOSITIONS FOR ULTRAVIOLET PROTECTION OF SKIN Mary Kay, Inc. (US) 2026-05-13 EP disclosed
US-12622866-B2 Topical compositions and methods MARY KAY INC. (US) 2026-05-12 US disclosed
EP-4734912-A2 HIGH SEPARATION DUAL PHASE EYE MAKE-UP REMOVER Mary Kay, Inc. (US) 2026-05-06 EP disclosed
US-12616644-B2 Polyurethane gels GRANT INDUSTRIES, INC. (US) 2026-05-05 US disclosed
US-20260115118-A1 COSMETIC COMPOSITIONS COMPRISING DRAGLINE SPIDER SILK SEEVIX MATERIAL SCIENCES LTD. (IL) 2026-04-30 US disclosed
WO-1998008597-A1 EMULSIFIER BLENDS FOR OIL-IN-WATER EMULSIONS R.I.T.A. CORPORATION (US) 1998-03-05 WO disclosed
US-5585091-A SUNSCREEN AGENT HAARMANN & REIMER GMBH (DE) 1996-12-17 US disclosed
US-5478560-A Containing salt of L-arginine-L-aspartic acid; moisturizer SHISEIDO COMPANY LTD. (JP) 1995-12-26 US disclosed
EP-0506956-B1 EXTERNAL PREPARATION FOR SKIN SHISEIDO CO LTD (JP) 1995-02-22 EP disclosed
US-5286476-A Conditioner containing high molecular weight polysiloxane and low boiling oil SHISEIDO COMPANY LTD. (JP) 1994-02-15 US disclosed
EP-0506956-A1 EXTERNAL PREPARATION FOR SKIN SHISEIDO COMPANY LIMITED (JP) 1992-10-07 EP disclosed
US-4284621-A SUNSCREEN FOR SKIN BAYER AKTIENGESELLSCHAFT (DE) 1981-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115118-A1 COSMETIC COMPOSITIONS COMPRISING DRAGLINE SPIDER SILK CUTA, MC1R, SPPL2B KDM4E 4276/4885CA12 3488/4885CA1 4834/4885
US-12622866-B2 Topical compositions and methods ACACB, SHARPIN, AK1 KDM4E 170/4885CA12 1938/4885CA1 2682/4885
US-12616644-B2 Polyurethane gels DAGLB, DEGS1, CUTA KDM4E 1844/4885CA12 1512/4885CA1 2371/4885
US-20060073106-A1 Novel stabilized cinnamic ester sunscreen compositions SUN2, NISCH, BCAS2 KDM4E 1082/4885CA12 3467/4885CA1 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.